Evidence map›Paper›PMID 24807806›Full record

ArticleGene therapy2014

Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.

S E Gombash, F P Manfredsson, R J Mandel, T J Collier, D L Fischer, C J Kemp, N M Kuhn, S L Wohlgenant, S M Fleming, C E Sortwell

Abstract readComparative Study
In one paragraph

Article in Gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Downregulation of striatal CaNeurobiology of disease · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.Movement disorders : official journal of the Movement Disorder Society · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional Restoration.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

S E Gombash1] Graduate Program in Neuroscience, University of Cincinnati, Cincinnati, OH, USA [2] Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
F P ManfredssonDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
R J MandelDepartment of Neuroscience, Powell Gene Therapy Center, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA.
T J CollierDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
D L FischerDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
C J KempDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
N M KuhnDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
S L WohlgenantDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
S M FlemingDepartments of Psychology and Neurology, University of Cincinnati, Cincinnati, OH, USA.
C E SortwellDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Michigan State University · USUniversity of Cincinnati · USFlorida College · US

Funding

STN Deep Brain Stimulation and NeuroprotectionP50NS058830 · NINDS · UNIVERSITY OF CINCINNATI · PI COLLIER, TIMOTHY J. · 2009 to 2015
$5.9M
Pleiotrophin Overexpression to Facilitate Repair and Graft Efficacy in ParkinsoniR01NS058682 · NINDS · UNIVERSITY OF CINCINNATI · PI SORTWELL, CARYL E · 2007 to 2011
$1.6M
Training in neuromuscular diseasesT32NS077984 · NINDS · OHIO STATE UNIVERSITY · PI GUTTRIDGE, DENIS C, MENDELL, JERRY ROY · 2012 to 2016
$946k
Pleiotrophin for Neurorestoration in Parkinson's DiseaseF31NS076158 · NINDS · UNIVERSITY OF CINCINNATI · PI GOMBASH LAMPE, SARA ELIZABETH · 2012 to 2013
$41k
NINDS NIH HHS F31 NS076158NINDS NIH HHS NS058682NINDS NIH HHS NS058830NINDS NIH HHS NS076158NINDS NIH HHS P50 NS058830NINDS NIH HHS R01 NS058682NINDS NIH HHS T32 NS077984
6 · The paper itself

Abstract

Intrastriatal injection of recombinant adeno-associated viral vector serotype 2/1 (rAAV2/1) to overexpress the neurotrophic factor pleiotrophin (PTN) provides neuroprotection for tyrosine hydroxylase immunoreactive (THir) neurons in the substantia nigra pars compacta (SNpc), increases THir neurite density in the striatum (ST) and reverses functional deficits in forepaw use following 6-hydroxydopamine (6-OHDA) toxic insult. Glial cell line-derived neurotrophic factor (GDNF) gene transfer studies suggest that optimal neuroprotection is dependent on the site of nigrostriatal overexpression. The present study was conducted to determine whether enhanced neuroprotection could be accomplished via simultaneous rAAV2/1 PTN injections into the ST and SN compared with ST injections alone. Rats were unilaterally injected in the ST alone or injected in both the ST and SN with rAAV2/1 expressing either PTN or control vector. Four weeks later, all rats received intrastriatal injections of 6-OHDA. Rats were euthanized 6 or 16 weeks relative to 6-OHDA injection. A novel selective total enumeration method to estimate nigral THir neuron survival was validated to maintain the accuracy of stereological assessment. Long-term nigrostriatal neuroprotection and functional benefits were only observed in rats in which rAAV2/1 PTN was injected into the ST alone. Results suggest that superior preservation of the nigrostriatal system is provided by PTN overexpression delivered to the ST and restricted to the ST and SN pars reticulata and is not improved with overexpression of PTN within SNpc neurons.

Indexed as

AnimalsCarrier ProteinsCell LineCorpus StriatumCytokinesDependovirusDisease Models, AnimalGenetic TherapyGenetic VectorsMaleNeurodegenerative DiseasesNeuroprotective AgentsOxidopamineRatsRats, Sprague-DawleySubstantia NigraCarrier ProteinsCytokinesNeuroprotective AgentsOxidopaminepleiotrophin

Identifiers

PMID24807806
PMCPMC4326069
OpenAlexW2085898938

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.